Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients.
Company profile
GSK
Pipeline26 assets
- ArexvyArexvy / RSV F protein / Recombinant protein, adjuvanted vaccine / Infectious diseasesRSV adults (50-59 years of age at increased risk)Phase III/Registration
- gepotidacinGSK2140944 / Bacterial topoisomerase inhibitor / Small molecule / Infectious diseasesUrogenital gonorrhoeaPhase III/Registration
- bepirovirsenGSK3228836 / HBsAg / Antisense oligonucleotide / Infectious diseasesChronic HBV infectionPhase III
- BexseroBexsero / MenB / Recombinant protein, OMV vaccine / Infectious diseasesMeningitis B (infants US)Phase III/RegistrationUS
- MenABCWY vaccineGSK3536819 / Meningococcal ABCWY / Recombinant protein, OMV, conjugated vaccine / Infectious diseasesMeningococcal diseasePhase III/Registration
- Nucala (mepolizumab)Nucala / IL-5 / Monoclonal antibody / Respiratory/ImmunologyCOPD with eosinophilic phenotypePhase III/Registration
- depemokimabGSK3511294 / IL-5 / Monoclonal antibody / Respiratory/ImmunologyAsthma with type 2 inflammationPhase III/RegistrationChronic rhinosinusitis with nasal polypsPhase III/RegistrationEGPAPhase III
- camlipixantGSK4523199 / P2X3 / Small molecule antagonist / Respiratory/ImmunologyRefractory chronic coughPhase III
- linerixibatGSK2330672 / IBAT / Small molecule / Respiratory/ImmunologyCholestatic pruritus in primary biliary cholangitisPhase III
- Blenrep (belantamab mafodotin)GSK2857916 / Blenrep / BCMA / Antibody-drug conjugate / OncologyRelapsed/refractory multiple myelomaPhase III/Registration
- Jemperli (dostarlimab)Jemperli / PD-1 / Monoclonal antibody / OncologyEndometrial cancerPhase III/RegistrationRectal cancer (dMMR)Phase IINon-small cell lung cancerPhase III
- Zejula (niraparib)Zejula / PARP / Small molecule / OncologyOvarian cancerPhase III/Registration
- belrestotugGSK4428859 / TIGIT / Monoclonal antibody / OncologyNSCLC and other solid tumorsPhase III
- GSK5764227GSK5764227 / B7-H3 / Antibody-drug conjugate / OncologyExtensive-stage small-cell lung cancerPhase IIIAdvanced GI solid tumorsPhase I/II
- cobolimabGSK4069889 / TIM-3 / Monoclonal antibody / OncologyNon-small cell lung cancerPhase II/III
- GSK4532990GSK4532990 / HSD17B13 / RNA interference / Opportunity drivenNASH/MASHPhase II
- GSK4172239GSK4172239 / DNMT1 / Small molecule inhibitor / Opportunity drivenSickle cell diseasePhase I
- GSK3882347GSK3882347 / FimH / Small molecule antagonist / Infectious diseasesUncomplicated UTIPhase I
- GSK3923868GSK3923868 / PI4K beta / Small molecule inhibitor / Infectious diseasesRhinovirus diseasePhase I
- GSK3965193GSK3965193 / PAPD5/PAPD7 / Small molecule inhibitor / Infectious diseasesChronic HBV infectionPhase I
- GSK2556286GSK2556286 / Mtb cholesterol-dependent / Small molecule inhibitor / Infectious diseasesTuberculosisPhase I
- GSK3772701GSK3772701 / P. falciparum whole cell / Small molecule inhibitor / Infectious diseasesMalariaPhase I
- GSK4024484GSK4024484 / P. falciparum whole cell / Small molecule inhibitor / Infectious diseasesMalariaPhase I
- GSK3536867GSK3536867 / Salmonella typhoid + paratyphoid A / Bivalent conjugate vaccine / Infectious diseasesSalmonella (typhoid + paratyphoid A)Phase I
- AGN-151586 / progranulin program (latozinemab)AL001 / Progranulin/sortilin / Monoclonal antibody / Opportunity drivenFrontotemporal dementia with progranulin gene mutationPhase III
Latest news25 items
All newsHibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B
First global approval for Hibsago
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
Superiority data from LATA together with OPERA findings add to the clinical and real-world evidence base for long-acting injectable Cabenuva
Presentation / AbstractAIDS 2026 presentations Wed, Jul 29, 2026
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
ARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relapsed osteosarcoma
Trial Results • Phase 3ARTEMIS-011 trial results Tue, Jul 28, 2026
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Positive Week 48 data from the phase IIIb VOGUE study reinforce Dovato as an effective treatment option with fewer medicines than Biktarvy
Presentation / Abstract • Phase 3AIDS 2026 presentation Mon, Jul 27, 2026
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC.
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026
VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen Dovato with 3-drug regimen Biktarvy
Presentation / Abstract • Phase 3AIDS 2026 oral presentation Tue, Jul 28, 2026, 10:30 AM
European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds
If approved, a single booster dose could help protect individuals who were previously vaccinated with Bexsero
GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)
GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials
Trial Results • Phase 3
GSK completes acquisition of Nuvalent, Inc.
GSK plc today announced completion of its acquisition of Nuvalent, Inc. , a Boston-based clinical-stage biopharmaceutical company.
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation and surgery in some patients
Trial Results • Phase 2
GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
Trial Results • Phase 3
Roy Jakobs to join GSK Board as Non-Executive Director
Roy Jakobs will join the Board of the Company as a Non-Executive Director from 13 July 2026.
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSK plc today announced that Harmony Row Acquisition Co. has commenced a tender offer to purchase all of the shares of Nuvalent, Inc.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
More than 3 million cases of cUTIs are treated annually in the US with up to a third of patients impacted by resistant infections.
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with no approved treatments.
GSK enters agreement to acquire Nuvalent, Inc.
Acquisition expected to be accretive to sales & core operating profit in 2027 & core EPS in 2029 inclusive of synergies and reprioritisation
Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Pivotal B-Well data show a significant 19% functional cure in the overall study population and 26% in patients with lower viral activity.
Trial Results • Phase 3
GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA
GSK will present new data from its expanding oncology portfolio and pipeline at ASCO and EHA.
Presentation / Abstract • Phase 3ASCO abstract release Fri, May 29, 2026
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk
First RSV vaccine approved for adults aged 18-59 years at increased risk and for all adults 60 years and older in Japan
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China
GSK presents latest respiratory research to advance patient care at ATS 2026
Patient preference and adherence research highlight potential of long-acting dosing regimens to improve clinical outcomes in severe asthma
Presentation / Abstract • Phase 3
GSK delivers strong Q1 performance and start to 2026
Q1 2026 highlights